Regulus adds Biogen to partner roster
This article was originally published in Scrip
Executive Summary
Regulus Therapeutics and Biogen Idec have entered into a collaboration to identify microRNAs as biomarkers for multiple sclerosis. Biogen will invest in Regulus and pay the San Diego-based company undisclosed upfront and milestone fees.